Robotic Urologic Surgery: Trends in Food and Drug Administration-Reported Adverse Events Over the Last Decade

被引:8
|
作者
Nik-Ahd, Farnoosh [1 ]
Souders, Colby P. [2 ]
Houman, Justin [2 ]
Zhao, Hanson [2 ]
Chughtai, Bilal [3 ]
Anger, Jennifer T. [2 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Cedars Sinai Med Ctr, Dept Surg, Div Urol, Los Angeles, CA 90048 USA
[3] Weill Cornell Med Ctr, Dept Urol, New York, NY USA
关键词
robotic surgery; da Vinci; adverse events; malfunction; MAUDE; SURGICAL SYSTEM;
D O I
10.1089/end.2018.0802
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: The da Vinci Surgical System has led to a rapid growth in the volume of robot-assisted surgeries, with 877,000 surgeries performed in 2017. Despite the increasing prevalence of robotic urologic surgeries, few long-term studies exist that examine trends in reported adverse events (RAEs). We analyzed RAEs over the past decade. Materials and Methods: We extrapolated all entries from the Manufacturer and User Facility Device Experience (MAUDE) database with the manufacturer "Intuitive Surgical" from 2007 to 2017. Reports were analyzed for date and type of RAE (death, bodily injury, malfunction, and other). RAEs from urologic surgeries were analyzed further for specific information pertaining to death, bodily injury, and malfunction. Results: A total of 19,783 RAEs were analyzed. Instrument or robot malfunctions comprised the majority of RAEs (84.9%); bodily injuries comprised 8.2%. Death was the least common RAE (1.3%). RAEs for urologic robotic surgeries peaked in 2013 and 2014 and decreased since. A total of 69 (2.3%) deaths, 364 (12.2%) injuries, and 2544 (85.5%) instrument or robot malfunctions occurred. No reported deaths were attributed to system or mechanical malfunction, but rather to medical complications reported to be unrelated to surgery. The most common injuries were bowel (22.3%) and genitourinary (GU) (19.5%). Instrument malfunctions caused 16.8% of bodily injuries. Conclusions: RAEs for robotic urologic surgeries peaked in 2013 to 2014, and have decreased annually since. When malfunctions occurred, they did not result in death and infrequently resulted in bodily injury. Potential quality improvement targets include prevention of bowel and GU injuries through surgical coaching, and improved technology to prevent malfunction of the surgical system and instruments.
引用
收藏
页码:649 / 654
页数:6
相关论文
共 50 条
  • [1] Robotic urologic surgery: trends in litigation over the last decade
    Farnoosh Nik-Ahd
    Colby P. Souders
    Hanson Zhao
    Justin Houman
    Lynn McClelland
    Bilal Chughtai
    Jennifer T. Anger
    Journal of Robotic Surgery, 2019, 13 : 729 - 734
  • [2] Robotic urologic surgery: trends in litigation over the last decade
    Nik-Ahd, Farnoosh
    Souders, Colby P.
    Zhao, Hanson
    Houman, Justin
    McClelland, Lynn
    Chughtai, Bilal
    Anger, Jennifer T.
    JOURNAL OF ROBOTIC SURGERY, 2019, 13 (06) : 729 - 734
  • [3] Robotic sacrocolpopexy: adverse events reported to the FDA over the last decade
    Colby Souders
    Farnoosh Nik-Ahd
    Hanson Zhao
    Karyn Eilber
    Bilal Chugtai
    Jennifer Anger
    International Urogynecology Journal, 2019, 30 : 1919 - 1923
  • [4] ROBOTIC SACROCOLPOPEXY: ADVERSE EVENTS REPORTED TO THE FDA OVER THE LAST DECADE
    Souders, Colby P.
    Zhao, Hanson
    Nik-Ahd, Farnoosh
    Chughtai, Bilal
    Anger, Jennifer T.
    NEUROUROLOGY AND URODYNAMICS, 2018, 37 : S680 - S681
  • [5] Robotic sacrocolpopexy: adverse events reported to the FDA over the last decade
    Souders, Colby
    Nik-Ahd, Farnoosh
    Zhao, Hanson
    Eilber, Karyn
    Chugtai, Bilal
    Anger, Jennifer
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2019, 30 (11) : 1919 - 1923
  • [6] A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole
    Labenz, J
    Petersen, KU
    Rösch, W
    Koelz, HR
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) : 1015 - 1019
  • [7] Adverse Events Associated with Microinvasive Glaucoma Surgery Reported to the Food and Drug Administration
    Duong, Andrew T.
    Yuan, Melissa
    Koenig, Lisa R.
    Rodriguez, Geoffrey H.
    Van Tassel, Sarah H.
    OPHTHALMOLOGY GLAUCOMA, 2021, 4 (04): : 433 - 435
  • [8] Ivermectin adverse events reported to the food and drug administration
    Avila, Maximillian
    Caceres-Munoz, Alba
    Patel, Arpan
    De la Cruz, Pablo Frias
    Mandair, Satpreet
    Young, Amy
    Forrester, Mathias
    CLINICAL TOXICOLOGY, 2022, 60 : 63 - 63
  • [9] Cannabidiol adverse events reported to the Food and Drug Administration
    Menendez, Anelle
    Hinojosa, Maria
    Jaramillo-Stametz, Jeanie
    Forrester, Mathias B.
    CLINICAL TOXICOLOGY, 2020, 58 (11) : 1177 - 1178
  • [10] Capsaicin adverse events reported to the Food and Drug Administration
    Hogue, Kelly
    Petty, Lizbeth
    Forrester, Mathias B.
    CLINICAL TOXICOLOGY, 2020, 58 (11) : 1148 - 1149